» Articles » PMID: 24880032

Decrease in Neuroimmune Activation by HSV-mediated Gene Transfer of TNFα Soluble Receptor Alleviates Pain in Rats with Diabetic Neuropathy

Overview
Publisher Elsevier
Date 2014 Jun 1
PMID 24880032
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms of diabetic painful neuropathy are complicated and comprise of peripheral and central pathophysiological phenomena. A number of proinflammatory cytokines are involved in this process. Tumor necrosis factor α (TNF-α) is considered to be one of the major contributors of neuropathic pain. In order to explore the potential role of inflammation in the peripheral nervous system of Type 1 diabetic animals with painful neuropathy, we investigated whether TNF-α is a key inflammatory mediator to the diabetic neuropathic pain and whether continuous delivery of TNFα soluble receptor from damaged axons achieved by HSV vector mediated transduction of DRG would block or alter the pain perception in animals with diabetic neuropathy. Diabetic animals exhibited changes in threshold of mechanical and thermal pain perception compared to control rats and also demonstrated increases in TNFα in the DRG, spinal cord dorsal horn, sciatic nerve and in the foot skin, 6 weeks after the onset of diabetes. Therapeutic approaches by HSV mediated expression of p55 TNF soluble receptor significantly attenuated the diabetes-induced hyperalgesia and decreased the expression of TNFα with reduction in the phosphorylation of p38MAPK in the spinal cord dorsal horn and DRG. The overall outcome of this study suggests that neuroinflammatory activation in the peripheral nervous system may be involved in the pathogenesis of painful neuropathy in Type 1 diabetes which can be alleviated by local expression of HSV vector expressing p55 TNF soluble receptor.

Citing Articles

The Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy: New Lessons from Experimental Studies and Clinical Implications.

Panou T, Gouveri E, Popovic D, Papazoglou D, Papanas N Diabetes Ther. 2025; 16(3):371-411.

PMID: 39928224 PMC: 11868477. DOI: 10.1007/s13300-025-01699-7.


Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls.

Shinu P, Morsy M, Nair A, Al Mouslem A, Venugopala K, Goyal M J Clin Med. 2022; 11(11).

PMID: 35683390 PMC: 9181614. DOI: 10.3390/jcm11113002.


The role of dorsal root ganglia alpha-7 nicotinic acetylcholine receptor in complete Freund's adjuvant-induced chronic inflammatory pain.

Zhang X, Xu F, Wang L, Li J, Zhang J, Huang L Inflammopharmacology. 2021; 29(5):1487-1501.

PMID: 34514543 DOI: 10.1007/s10787-021-00873-0.


Redefining distal symmetrical polyneuropathy features in type 1 diabetes: a systematic review.

Galosi E, Hu X, Michael N, Nyengaard J, Truini A, Karlsson P Acta Diabetol. 2021; 59(1):1-19.

PMID: 34213655 PMC: 8758619. DOI: 10.1007/s00592-021-01767-x.


Cutaneous Neuroimmune Interactions in Peripheral Neuropathic Pain States.

Lowy D, Makker P, Moalem-Taylor G Front Immunol. 2021; 12:660203.

PMID: 33912189 PMC: 8071857. DOI: 10.3389/fimmu.2021.660203.


References
1.
Fernandez-Real J, Ricart W . Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003; 24(3):278-301. DOI: 10.1210/er.2002-0010. View

2.
Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

3.
Hills C, Brunskill N . Cellular and physiological effects of C-peptide. Clin Sci (Lond). 2009; 116(7):565-74. DOI: 10.1042/CS20080441. View

4.
Skundric D, Lisak R . Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res. 2003; 4(4):303-12. PMC: 2478613. DOI: 10.1155/EDR.2003.303. View

5.
Hao S, Mata M, Glorioso J, Fink D . Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007; 14(13):1010-6. DOI: 10.1038/sj.gt.3302950. View